Sugi Predict

Sugi Predict / Compounds / SCHEMBL193908

SCHEMBL193908

SCHEMBL193908

O=C(Cl)c1cc(F)c(F)c(F)c1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 5/20 0.64
▸ CES1 P23141 5/20 0.64
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA4 P22748 2/20 0.41
▸ ALDH1A1 P00352 3/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ HDAC1 Q13547 4/20 0.35
▸ HDAC6 Q9UBN7 4/20 0.35
▸ MAOB P27338 1/20 0.34
▸ LMNA P02545 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ KCNQ3 O43525 1/20 0.32
▸ KCNQ2 O43526 1/20 0.32
▸ KCNE1 P15382 1/20 0.32
▸ KCNQ1 P51787 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5948933 0.88 CES2 (0.50) CES2CES1CA1CA2CA4
SCHEMBL7922027 0.86 CES2 (0.48) CES2CES1CA1CA2CA4
SCHEMBL28829562 0.85 CES2 (0.48) CES2CES1CA1CA2CA4
SCHEMBL12377615 0.84 CES2 (0.46) CES2CES1CA1CA2CA4
SCHEMBL7922005 0.82 CES2 (0.42) CES2CES1ALDH1A1ALOX15HDAC1
SCHEMBL24670816 0.80 CES2 (0.41) CES2CES1ALDH1A1ALOX15HDAC1
SCHEMBL987144 0.80 HDAC1 (0.57) CES2CES1ALDH1A1ALOX15HDAC1
SCHEMBL11878100 0.80 HDAC1 (0.57) CES2CES1CA1CA2ALDH1A1
SCHEMBL21623109 0.80 CES2 (0.42) CES2CES1CA1CA2CA4
SCHEMBL2301770 0.79 ALDH1A1 (0.44) CES2CES1CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116410106-B Benzamide HBV capsid protein inhibitor and preparation method and application thereof 山东第二医科大学 2024-12-06 — — CN claimed
CN-118619832-A Resveratrol-based fluorine-containing active ester compound and preparation method and application thereof 广东工业大学 2024-09-10 — — CN claimed
CN-118598750-A Fluorine-containing active ester compound and preparation method and application thereof 广东工业大学 2024-09-06 — — CN claimed
CN-116410106-A Benzamide HBV capsid protein inhibitor and preparation method and application thereof 潍坊医学院 2023-07-11 — — CN claimed
CN-115703648-A Modified zinc oxide, preparation method thereof and light-emitting diode TCL科技集团股份有限公司 2023-02-17 — — CN claimed
CN-110283080-A A kind of fluorine-containing benzophenone derivates and its preparation method and application 山西大学 2019-09-27 — — CN claimed
EP-4713018-A1 TRANSFECTION COMPOSITIONS SUITABLE FOR PRODUCING A BIOLOGICAL PRODUCT PolyPlus Transfection (FR) 2026-03-25 — — EP disclosed
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 — — US disclosed
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-10-09 — — US disclosed
US-12384790-B2 Pteridinone compounds and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-08-12 — — US disclosed
US-12304907-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-05-20 — — US disclosed
EP-4536653-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME Eisai R&D Management Co., Ltd. (JP) 2025-04-16 — — EP disclosed
US-12264154-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-04-01 — — US disclosed
US-5773236-A FLUORESCENT DYES FOR DETECTION OF ENZYMES FOR METABOLISM IN CELLS MOLECULE PROBES, INC. (US) 1998-06-30 — — US disclosed
US-5773646-A INTEGRIN INHIBITORS G. D. SEARLE & CO. (US) 1998-06-30 — — US disclosed
EP-0825164-A2 Scavenger assisted combinatorial process for preparing libraries of amides, carbamates and sulfonamides ELI LILLY AND COMPANY (US) 1998-02-25 — — EP disclosed
WO-1997036862-A1 META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS G.D. SEARLE & CO. (US) 1997-10-09 — — WO disclosed
WO-1997026300-A1 COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED INDANE LIBRARIES ELI LILLY AND COMPANY (US) 1997-07-24 — — WO disclosed
US-5624601-A Silacyclohexane compounds, a liquid crystal composition comprising the same and a liquid crystal device comprising the composition SHIN-ETSU CHEMICAL CO., LTD. (JP) 1997-04-29 — — US disclosed
EP-0708107-A1 Novel silacyclohexane compounds, a liquid crystal composition comprising the same and a liquid crystal device comprising the composition SHIN-ETSU CHEMICAL CO., LTD. (JP) 1996-04-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME NEU1, NEU2, NEU4 CES2 775/4885CES1 1386/4885CA1 95/4885
US-12264154-B2 Compounds and methods of use F12, C1R, ABCG2 CES2 108/4885CES1 194/4885CA1 1719/4885
US-12304907-B2 Compounds and methods of use F12, C1R, ABCG2 CES2 108/4885CES1 194/4885CA1 1719/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 CES2 115/4885CES1 50/4885CA1 701/4885
US-12384790-B2 Pteridinone compounds and uses thereof DPYD, PKD1, TYMP CES2 4730/4885CES1 1773/4885CA1 4651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.